INTRODUCTION
Matrix metalloproteinases or matrixins (MMPs) represent a family of structurally related enzymes that belong to the large group of zinc-dependent metallopeptidases, sometimes called metzincins. Metzincins can be divided into 4 groups according to their mode of zinc binding -astacins, reprolysins (ADAMs enzymes), serralysins and matrixins. MMPs have been found in both vertebrates, and invertebrates, and even in plants. Evolutionarily, however, they developed from far lower organisms as protein sequence homology showes that amino acid sequence for metalloproteinase toxin-2 of Bacteroides fragilis has 59 % homology with 27 amino acid chain of human interstitial collagenase (MMP-1)(ref. 1 ). These enzymes not only take part in biological processes, such as degradation of connective tissue, and ontogenesis (morphogenesis, angiogenesis, growth), but also processes associated with wound healing [2] [3] [4] . Changes in MMP expression and activity can be observed in most inflammatory, degenerative, and especially malign processes associated with increased synthesis, degradation or impaired maturation and organization of extracellular matrix (ECM)(ref. [5] [6] [7] [8] ). There are also other enzymes, such as cystyl-and seryl-proteases group and other metallopeptidases participating in ECM degradation. 24 human matrix metalloproteinases were known at the time of preparing this review ( abbreviated MMP plus an Arabic numeral). The overview of MMPs is listed in Table 1 .
STRUCTURE OF MATRIX METALLOPROTEINASES
Matrix Metalloproteinases are homologous proteins which can be divided into 6 groups according to their common features: collagenases, stromelysins, matrilysins, gelatinases, membrane-type metalloproteinases (MT-MMPs) and other MMPs, namely zinc-and calcium-dependent endopeptidases. While the classification to 6 basic groups is probably the most known among sciences, they have been published other classifications e.g. a) classification based on solubility: soluble MMPs, membrane-associated MMPs and CA (cystein array) MMP; b) classification into 9 subgroups on the basis of their structures and substrate specifities: collagenases, gelatinases, stromelysins, matrilysins, furin-activated secreted MMPs, transmebranetype MMPs, GPI (glycophosphatidyl inositol)-anchored MT-MMPs, type II transmembrane MMPs and other MMPs [9] [10] [11] . MMPs are synthetized in the form of preproenzymes. They are usually secreted from the cell as inactive proenzymes (beside the membrane MMPs). A proenzyme molecule is organized into the 3 basic structural domains: N-terminal propeptide, catalytic domain, and the C-terminal part of the molecule ( Fig. 1 )(ref. 1 ). Nterminal propeptide consists of approximately 80-90 amino acids containing cysteine residue which interacts with catalytic zinc via its side chain thiol group (so called cystein switch), and this ensures the enzymatic latency of the proenzyme. Elimination of a highly conserved sequence (…PRCGXPD…) presented in the propeptide causes activation of zymogene 12, 13 . The catalytic domain (approximately 170 amino acids) consists of the zinc-binding motive HEXXHXXGXXH and anchored methionine, which forms a unique structure, called Met-turn. Incidentally, this very structure is typical for the other metzincins to which MMPs belong 14 . This domain consists of five-stranded β-sheet, three α-helixes, and bridging loops. The catalytic domain consists of two zinc (II+) ions and 2-3 Ca 2+ ions. One Zn 2+ appears in the active site and participates directly in the catalytic processes, the second Zn 2+ (structural) together with Ca 2+ are approximately 12 Å distant from Zn 2+ in the catalytic site 15 . The C-terminal domain shows structural similarity to proteins of the hemopexin family, including e.g. hemopexin, vitronectin or placental protein II (it has about 210 amino acid residues). An ellipsoidal disk shape with a four bladed β-propeller structure is typical for the Cterminal domain structure. Each blade consists of 4 antiparallel β-strands and an α-helix. The first and second blades are connected by a disulfide bond. The catalytic and C-terminal domains, as shown in collagenase-1, are covered as entities in crystal with a connecting flexible peptide linker or a hinge region, which is freely bound 16 . The length of this hinge is extremely variable: 16 residues in collagenases or by contrast, 65 residues in MMP-15. The function of the linker, which contains a lot of prolines and connects catalytic and hemopexin-like domains, is not completely known.
The hemopexin-like domain ( Fig. 1) , essential to collagenases, breaks down the interstitial collagen triplehelix, allowing the catalytic domain to manifest its proteolytic activity on other substrates 17 . By contrast, matrilysins do not have this domain. There is an additional transmembrane domain in the membrane-type matrix metalloproteinases (MT-MMPs) that binds (anchors) the enzyme to the cell surface. This domain consists of a hydrophobic chain containing approximately 25 amino acids with a recognizing motive RXKR for the furin-like convertases at the end of the propeptide chain (with the exception of MT4-MMP and MT6-MMP). MT4-MMP and MT6-MMP are tethered to the cell surface via a glycosylphosphatidylinositol (GPI) memrane anchor 1, [18] [19] [20] . Gelatinases consist of a domain having structural similarity to the matrix proteins. Three tandems of replicas of domain (58 amino acids) with the sequence fibronectin type II -like module of collagen bonding domain are found in all gelatinases, while a collagen type V -like module occurs only in longer gelatinases 21 .
On the other hand, matrilysins (MMP-7. MMP-26) have no hemopexin-like domain, making them the smallest MMP molecules. MMP-23 contains, in addition to the structure of matrilysins, a hydrophobic signal N-terminal anchor and cystein array 22, 23 . MMP-19, MMP-20, MMP-27 and MMP-12 can be classified as a new MMP group because it has no of the significant structural features of existing groups [24] [25] [26] [27] . Some other MMPs contain a recognizing motive for the protein convertase RXRXKR, e.g. MT-MMPs and stromelysine-3 in their molecules 28 .
MECHANISM OF EFFECT AND SUBSTRATE SPECIFICITY OF MMPS
Most of MMPs are able to degrade both majority and minority components of extracellular matrix; therefore, a lot of MMPs have wide substrate specificity. MMP-11 and MMP-23, whose ability to cleave the components of ECM is very low, are remarkable exceptions. This, however, does not exclude their ability to cleave other molecules (e.g. MMP-11 cleaves serpin) 29, 30 . MMPs also cleave or activate molecules which are not components of ECM (e.g. MMP-2,3,7 cleave decorin that is an important reservoir of TGF-β 1 . Cleavage of decorin initiates a release of the growth factor into the tissue which activates processes which are not necessarily directly connected with the extracellular matrix 31 .
Collagenases
Collagenases, compared to other MMPs, break down the native helix of collagen without previous denaturation of the molecule at neutral pH and include MMP-1, -8, -13 (see Tab. 1). They break down the α chain of the interstitial collagen (types I, II, III) into 2 specific parts, 1/4 and 3/4 fragments, in the site of the molecule that has a relaxed triplehelix and which contains a more hydrophobic group. There is a sequence Gly 37 . De Souza and others suggest that the interstitial collagenases "hinge-domain", rich in proline, simulates the collagen-like conformation 38 . With this domain, the enzyme is able to destroy the quaternary structure of the collagen triplehelix. Both similar structures of collagen and collagenase interact together forming a so called proline zipper. This destabilizing step leads to the following cleavage. The catalytic domain then breaks down only one fiber of collagen triplehelix in the relaxed structure. After this cleavage other MMPs can also participate in the following cleavage. The hemopexin-like domain also plays a certain role in stabilizing indirectly the procollagen-like domain of collagenase. Another possibility is that this domain ensures a nonfunctional bond of the substrate and then the "hinge-domain" ensures correct orientation of the substrate before its cleavage 39 . Membrane-type MMPs manifest approximately the same substrate specificity as analogous free MMPs. Collagen is not only the substrate for MT-MMPs. They also differ in activity (e.g. MMP-14 is 5-7 times less effective in cleavage of type I hydrolyzed collagen than analogous MMP-1 but in contrast manifests an 8 times higher gelatinolytic activity than MMP-1 40 ). MT4-MMP breaks down gelatin and synthetic substrates but it is intact to collagen type I and IV, fibronectin or laminin 41 . Others are able to break down proMMPs and thus activate them (in detail see the MMPs activation and inhibition).
Gelatinases
This category includes MMP-2 and MMP-9 (see Table 1 ). In particular gelatinases break down denatured collagen, type IV intact collagen of basal membranes and also non-denatured collagens type V, VII, X, XIV, fibronectin, agrecan, and elastin. MMP-2 is even considered to break down type I native collagen 34 . Further studies showed that it only binds intact collagen to prevent its autolytic inactivation 42 . Besides gelatin and other forms of denatured collagen, MMP-9 breaks down a whole range of other physiological substrates 43, 44 . Although the cleaved sequences are not yet fully identified, the main one which was cleaved by a majority of MMPs (not only MMP-9), contains a Pro-X-X-Hy-(Ser/Thr) motive where X is any amino acid residue and Hy is hydrophobic amino acid residue in position P 3 to P 2 . Another group contained Gly-Leu-(Lys/Arg) motive in a position between P 1 and P 2 . The last group of substrates contained arginine residues both in P 1 and P 2 and these substrates were explicitly preferred by MMP-9(ref. 45 ).
Stromelysins
The substrate specificity of stromelysins is relatively wide. They break down all non-collagen ECM proteins (proteoglycans, glycoproteins, fibronectin, and laminin). Type IV collagen is cleaved by stromelysins only in globular but not in helical conformation. Stromelysines include MMP-3, MMP-10, MMP-11 (see Table 1 ).
Macrophagous elastase and other MMPs
This category includes MMPs with the ability to break down other molecules. Macrophagous elastase (MMP-12) shares its ability to break down elastin with only a few MMPs (gelatinases and matrilysins) and is also able to break down fibronectin, laminin, basal membrane collagen, entactin, chondrotin sulfate and others 46 . This enables macrophages to penetrate basal membranes and thus subsequently remodel the tissue affected by inflammation. However, basal membranes are also degraded by MMP-19 27 . Components of enamel (mainly majority emalogenin) are specifically degraded by MMP-20(ref. 47 ). Many MMPs (MMP-3, MMP-13 and MMP-8, MT1-MMP) break down in vitro IGD agrecan bond in the position Asn 341 -Phe 342 (ref.
15
).
MATRIX METALLOPROTEINASES ACTIVATION AND INHIBITION
Regulation of MMPs activity is a complex process. It includes various levels of activation of latent MMPs, inhibition, secretion of the enzyme molecule and the regulation of gene transcription or inhibition of MMPs activity by tissue inhibitors of metalloproteinases (TIMPs). The selective expression of genes for tissue-specific MMPs and their inducibility by biologically active molecules (growth factors, cytokines, oncogenes, tumor promoters) are presently being studied.
a) Regulation of MMPs gene expression
Most genes for MMPs are inducible; besides biologically active molecules, genes can be induced by various chemical agents such as phorbol esters 48 . Gene expression can be inhibited by some suppressive factors (TGF-β, glucocorticoids, retinoic acid)(ref. 49, 50 ). Genes for MMPs are expressed only if the tissue, whether under physiological or pathological conditions, is remodeled. MMP-2 is an exception; regulation is realized at the level of activation and inhibition of enzyme activity 51, 52 . Promoters for most MMP genes include the same AP-1 element in position -70 and one or two replicas of PEA-3 element in position between -140 and -200. The first one reacts with Fos and Jun proto-oncogene family. PEA-3 element reacts with Ets family of transcription factors. Mutation analyses showed that the AP-1 sequence itself or in combination with PEA-3 regulate the basic stages and inducibility of these genes by means of various molecules. Transcription factors which recognize these sites are the already mentioned proto-oncogenes in the cis conformation (cis-elements). For example, stromelysin-1 PDGF responsive element (SPRE). One of these transcription factors, recognizes the site -1573 on the gene for MMP-3, but it has also been identified on other promoters of MMP genes; therefore it generally results in regulation of MMP gene expression 20 . There are a number of described signaling pathways resulting in the MMPs expression. Inflammatory cytokines, TNF-α and IL-1 trigger ceramide signaling. Ceramide-dependent expression of MMP-1 in human dermal fibroblast is influenced by the three distinct MAP kinase pathways, ERK1/2, stress-activated protein kinase (SAPK)/JNK and p38(ref. 53, 54 ). One inducible factor is also ultraviolet B irradiation, which increases expression of MMP-1, MMP-3 and MMP-9 in human dermal fibroblasts. Protein kinases JNK-2 are activated by stress via reactive free radicals and via lipid peroxidation 55, 56 . Gene expression is influenced also by the ECM-cell and cell-cell interactions. As an example, we can also mention glycoprotein EMMPRIN (extracellular matrix metalloprotinase inducer) that was first identified on the surface of human tumor cells. It stimulates MMP-1,-2 and -3 production in human fibroblasts and increases mRNA MMP-1 expression; this stimulating effect requires activity of p38 57, 58 . MMPs or EMMPRIN synthesis can also be influenced by the changed hemodynamic overload 59 . MMP-9 is induced by α 5 β 1 integrin-fibronectin interaction during the differentiation of macrophages 60 . MT1-MMP expression is triggered by the cells of endothelium, fibroblasts and also neoplastic cells via interaction by α 2 β 1 integrin 61 .
Natural sequence variations of MMP genes promoters can

b) Regulation of MMPs enzyme activity by cystein switch mechanism
MMPs are expressed as zymogens. There is a certain reserve of inactive MMP bonded to various components of ECM in the extracellular space. Certain stimuli lead to fast MMPs activation. MMP-2 binds to the ECM structures containing elastin, MMP-3 to basal membranes and occasionally to collagen fibrils and MMP-13 to proteoglycans, collagen and elastin 62 . Not all MMPs are stored in latent forms. MMP-8 is in specific granules, MMP-1 and MMP-3 are constitutively produced after the release of cytokines and inflammatory mediators 64, 13 . The key step is dissociation of zinc-cystein interaction. Then zinc interacts with water. Extracellular activation of the enzyme includes 2 steps. The first is initial cleavage of the MMP propeptide by protease, destabilization of propeptide binding interactions, and break of coordination bond of cystein and Zn 2+ ions. The second step is the final cleavage of the propeptide, that is usually ensured by another MMP. The result is a matured enzyme. In many cases, MMPs cannot participate in reaction until the last part of the propeptide is removed. In MT-MMPs and stromelysine-3 the active site is formed directly after the previous interaction of 11 residues containing consensus RXKR (where X can be any amino acid) with the furine family of enzymes -with endopeptidases associated with the Golgi apparatus. Intracellular cleavage of MT-MMPs and stromelysine-3 by the furine-like enzyme activates the enzyme [65] [66] [67] . There are also alternative ways of MMPs activation. MT1-MMP is as an inactive zymogene located on the cell membranes. Gelatinase A (MMP-2) and collagenase-3 can be activated extracellularly on the surface of cells by the active, membrane bound MMP which, in this case, plays the role of enzyme and also membrane receptor. This activation process requires active MT-1-MMP and TIMP-2 bond to MT-1-MMP(ref. [68] [69] [70] ). ). In this way they protect binding sites for the substrates being split off 71 . TIMP-1 forms the complex preferentially with MMP-9, and TIMP-2 preferentially with MMP-2. The crystalline structure of the complex formed between TIMP-1 and catalytic domain MMP-3 has already been described: critical sites of the whole inhibition process are localized around a disulfide bond between Cys 1 and Cys 70 (ref. 72 ). The Nterminal α-amino and carbonyl groups of Cys 1 bidentately coordinate the Zn 2+ . Thus TIMPs prevent autocatalytic cleavage of the MMP molecule leading to the formation of the active molecule (mechanism of cystein switch). Active membrane bound MMPs can be inhibited with TIMPs in complexes with other molecules. A catalytic amount of MMP-3 considerably activate proMMP-9 in the absence of TIMP-1, but not the [proMMP-9-TIMP-1] complex. Thus MMP-3 is inhibited by TIMP-1(ref. 73, 74 ). If the ternary complex [proMMP-9-TIMP-1-MMP-3] is formed, interaction between proMMP-9 and TIMP-1 weakens and partially dissociates into free proMMP-9 and [TIMP-1-MMP-3] complex. Thus, a higher concentration of MMP-3 is needed for the activation of proMMP-9, which is inhibited by TIMP-1, which must be saturated by another matrixin 75 . This explains what impairs MMPs inhibition mediated by TIMPs. TIMP-1 expression is regulated by cytokines (TNF-α) which can modify TIMP-1 expression via induction of nuclear transcription factors, TIMP-2 expression by cytokine stimulation does not take place 76, 77 . TIMP-3 has been identified in the myocardium of the mouse embryo, where it probably takes part in ECM embryonal remodeling and heart development 78 . It differs from other TIMPs by direct binding to the ECM compo-
c) Inhibition of MMPs by means of TIMPs
Matrix metalloproteinases and their function in myocardium
nents (TIMP-1 and TIMP-2 are freely diffusible in the interstitial space). Therefore, TIMP-3 models MMP activity better than other TIMPs(ref. 79 ). TIMP-4 has been detected in low concentrations in kidneys and the colon. It is not in lungs, liver or the brain. By contrast, high TIMP-4 expression has been identified in the heart 80 . TIMPs also show other biological functions. TIMP-1 and TIMP-2 have mitogenic activity in various cell types, TIMP-2 influences interaction/adhesion between substrates and the cell 81, 82 . TIMPs overproduction slows down the growth of tumor cells. Decrease in TIMPs concentration during the healing of damaged tissue increases collagenolytic activity. Reduced TIMPs activity also enables tumor cells to impair the surrounding extracellular matrix, and thus they migrate to the adjacent tissues. Therefore it is clear that regulation of the balance between collagenases and their inhibitors is necessary for remodeling of tissue whose impairment can significantly change the tissue functional characteristics 83 .
MMPS AND CARDIAC TISSUE
Structure and Function of Myocardial ECM
Cardiac tissue consists of the two basic components -cellular and extracellular. Two thirds of the total tissue content comprises myocytes, one third of cellular matrix is occupied by other cells -fibroblasts, endothelial cells, other cells and acellular components -extracellular tissue fluid and extracellular matrix. Pathological changes at the molecular level are characterized by the change in the qualitative and quantitative constitution of ECM and the constitution of myocytes. These changes are the result of tissue remodeling, as well as the changed synthesis, degradation, maturation and incorporation of individual ECM components that form a highly organized structure with not only structural but also regulating and communicative functions 84, 85 . Slow turnover of extracellular matrix is characteristic of healthy cardiac tissue: synthesis and degradation are in a dynamic balance. The structural backbone myocardial ECM is formed by a fibrillar collagenous network consisting, above all, of collagen type I and III that are extremely resistant to proteolytic cleavage. However, myocardial ECM also contains components in lower quantity, which connect individual components, communicate with myocytes, modulate transport and organization of ECM or individual components, influencing cellular signaling. Besides various minor collagens (type IV, V, VI, VII, VIII, IX, X, XV, XVIII and others)(ref. 86, 87 ) there is a whole range of glycoproteins, glycosaminglycans (heparan sulfate and chondroitin sulfate), microfibrilar proteins (fibrilin and fibulin), laminin, fibronectin, elastin, integrins, tenascins and others [88] [89] [90] . There are also various groups of enzymes which take part in degradation of ECM components in myocardium, such as the above discussed MMPs and ADAM metalloproteinasses, seryleproteases (plasmin, neutrophil elastase, cathepsin G), cysteine proteases (cathepsin B,L and S), aspartyl proteases (cathepsin D)(ref. 91 ).
MMPS AND DISEASE OF MYOCARDIUM
Myocardial remodeling in various pathological situations is characterized by several different processes of cardiac tissue turnover. The first, which is characteristic of myocardial infarct, is very similar to the process of any damaged tissue healing. The previous ischemic injury of the original tissue, is followed by a repair processes which removes necrotic tissue and replaces it with a new one. The second is a result of long-term reaction of cardiac tissue under volume-or pressure-overload. Thus, tissue turnover enables the maintenance of heart function even at changed pressure and volume conditions and leads to right-ventricular or left-ventricular heart failure. This is a qualitative and quantitative change of ECM components.
MMPs Function in Ischemic Cardiac Tissue
An acute ischemic phase (proteolytic and redox insult) activates MMPs and this results in the impairment of the ECM at the site of the ischemic injury; TIMP concentration is also changed. Later on, concentrations of MMP inhibitors are lowered, hence degradation of ECM components continues. This leads to dilatation and systolic failure. Continuous ECM synthesis at sites distal from infarcted area leads to fibrosis and diastolic failure. Structural remodeling of tissue after the myocardial infarct leads to development of hypertrophy and tissue stretching. These processed are then accompanied by development of fibrosis in the non-infarcted part of the heart and dilatation of the infarcted part. This together results in cardiac failure 92, 93 . After a myocardial infarct, MMP-1 in cardiac tissue is activated by the proteinases of inflammatory cells and at the same time considerable reduction in number of present TIMPs occurs 94, 95 . In ischemic left ventricle in rats, increased collagenolytic activity was found 2 days after coronary artery ligation, a maximum was reached after 7 days, and then a decrease in MMP-1 activity and a parallel increase in MMP-2 and MMP-9 activities were observed. An increase in mRNA MMP-1 expression was not detected earlier than 7 days after coronary artery ligation. TIMP mRNA transcription is already observed after 6 hours, a maximum is reached after 2 days of infarct. Post-translational activation of latent MMP-1 is, in the process of injured myocardial tissue healing, more important than transcription of appropriate mRNA proMMP-1. Transcription of MMP-1 occurs after depletion of latent enzyme amount. TIMP mRNA synthesis is regulated by activation of matrix metalloproteinases. Balance between collagenase activation and TIMP inhibition determines the stage of collagenolysis in infarcted tissue 96 . Hence, MMP-1 is not the enzyme which is fully responsible for collagen degradation in ischemic myocardium. Therefore, other enzymes from the group of cysteine proteases (e.g. plasmin) or lysosomal cysteine proteases (e.g. cathepsin G) are at work here 91 . Delayed reperfusion changes activity of MMPs in the infarcted focus of the rat's heart, as well as the lowering of activities of MMP-1, MMP-2 (50 % to 60 % after 7 days) and MMP-9 (up to 84 % after 48 hours) 97 . On the other hand, in early reperfusion, by means of initiated inflammatory processes, the secretion of active MMP-9 part by infiltrating neutrophils, probably activates proteasis of other MMPs and the mechanism of the infarcted focus turnover process is different. By contrast, inhibition of the inflammatory process is associated with an increased risk of ventricular aneurysms, cardiac ruptures and death 98 . MMP-2 release during reperfusion after ischemia contributes to the cardiac mechanical dysfunction. Specific inhibition of MMPs may be a new strategy in the treatment of ischemia-reperfusion injury 99 . For example, an early left ventricle hypertrophy was avoided by administration of broad spectrum MMP inhibitor (CP-471, 474) to mice with experimentally induced myocardial infarct 100 .
MMPs Function in Remodeling of Hypertrophic Cardiac Tissue
Pressure or volume overload of heart muscle leads to hypertrophy and consequent cardiac tissue remodeling.
In spontaneously hypertensive rats, the increase in MMPs activity (e.g. MMP-2, 9) appears during heart failure. TGF-β is a known inducer of collagens and TIMPs expression and inhibitor of MMPs (activity or expression). In spite of this, profibrotic components are increased during hypertrophic remodeling which leads to development of cardiovascular fibrosis and diastolic dysfunction 92 . In experimentally induced myocardial fibrosis in hypertensive rats, the increase in MMP-2 activity was detected after 2 months, while activity for MMP-1 remained unchanged 101 . Some studies also showed that the total MMPs activity in patients in the last stages of cardiomyopathies was increased 102, 103 . There is considerable selective reduction of tissue MMP inhibitor expression and independent increase in gelatinolytic activity presented by MMP-9 activity in the failing human heart 102 . In some hypertrophic cardiomyopathies, increase in tissue inhibitor concentration was detected, compared to controls, up to 100 times higher 104 , showing the exceptional position of TIMPs in the process of tissue remodeling.
We demonstrated increased expression of TIMP-1 mRNA (more than 3.5 times) and at the same time a 2.5 times increase in MMP-2 expression in hypertrophied right ventricle after the 14 days of hypoxic hypoxia (10 % O 2 ) in rats 105 . By contrast, the decrease in TIMP-1 and MMP-2 expression occurred after a 4-day hypoxic stimulus 106 .
MMPs and Dilated Cardiomyopathy
In dilated cardiomyopathies (DCM), ventricular wall weakening occurs, myocytes are hypertrophied and disruptions in ECM appear. The DCM result is systolic heart failure. It was demonstrated in hamster DCM models that MMPs activity was increased after 180 days and did not change within 310 days. This increased MMPs activity was associated with reduction in TIMPs expression 107 . Similarly in humans, MMP-1 is specifically and differentially induced, while TIMS expression is reduced (inhibited)(ref. 107 ). There are two possible explanations: it is either mutation, affecting the propeptide part of MMP-1, which leads to production of already active MMP-1 without the need for posttranslational activation or a dramatic reduction in the presence of MMP tissue inhibitors 104 . Beside MMP-1, MMP-3 and MMP-9 activities are also increased. Increased MMP-3 activity was detected during left ventrical dilatation in animals and humans 108, 103 . Pigs with congestive heart failure had MMP-1 activity higher by up to 319 % in the left ventricle, MMP-2 activity increased by 194 % and MMP-3 by 493 % in comparison with healthy animals 109 . The reduction of cross-links between collagenous fibrils also occurs during dilatation. Newly formed collagen is not connected by cross-links; collagenous depositions are made and they succumb to the increased turnover as a result of increased MMPs activity in the process of cardiac tissue dilatation. An interesting finding was that higher activity of neutrophil collagenase (MMP-8) was detected in human cardiac tissue at DCM 110 . In rats with symptomatic congestive heart failure, significant increase in MMPs activity occurr.. Some authors further showed that ventricular dilatation can develop even when synthesis of collagen considerably exceeds its degradation. It is clear that the concentration of the total collagen is not responsible for the process of ventricular compliance. However, decreased interation between collagen and integrin receptors, changes in collagen cross-linking or inner changes in architecture of cardiomyocytes play important roles in ventricular remodeling 111 .
SYNTHETIC INHIBITORS OF MMPS
Several chemotherapeutic agents, antibiotics and synthetic peptides modulated production or activity of different classes of MMPs, and were tested with varying success in animals and patients above all those with malignant diseases. Disruption of tissue organization is a hallmark of malignant growth, it creates space for local tumor invasion and allows the tumor cells to gain access to the vascular and lymphatic systems. Lately, great effort has been focused on the development of effective specific inhibitors of MMPs and their use in therapy of non-malignant diseases 8 . MMPs inhibitors can be divided into 4 groups: a) peptidomimetic inhibitors of MMPs, b) non-peptidomimetic inhibitors of MMPs, c) tetracycline derivates, d) biphosphonates. The structures of some of these are showen in Fig. 2. 
a) Peptidomimetic Inhibitors of MMPs
The first synthetic inhibitors of MMPs (peptidomimetic) were developed on the basis of our knowledge of the sequence of sites where collagenous molecules are cleaved by MMP-1. These inhibitors contain a chelating group which binds zinc in the MMP active site. BB-94 (Batimastat)(ref. 112 ) and this inhibits the right side of the cleavage site is a typical example of such inhibitor. 
Peptidomimetic inhibitors
Non-peptidomimetic inhibitors
Bisphosphonates
Modified tetracyclines . To maintain the constant structure of these inhibitors, a so called hydroxamate structure was chosen. The hydroxamate serves as an effective ligand of Zn 2+ ion in the MMP active site. Modification of the side chain of the hydroxamate (e.g. by the succinate) increases the inhibiting effect of these compounds. A group of these inhibitors (e.g. BB-94 or BB-1101) has broad substrate specificity. Further effort was made to develop a compound that would inhibit the right side as well as the left side of the cleavage site of the enzyme (e.g. SE205)(ref. 114 ). Peptidomimetic inhibitors have been successfully used in experimental cardiology. For example, administration of Batimastat prevented heart failure which would have been caused by myocardial hypertrophy development or by diastolic dysfunctions in young transgenic mice with enhanced expression of TNF-α (restricted to myocardium)(ref. 115 ).
b) Non-Peptidomimetic Inhibitors of MMP
The group of nonpeptidic (non-peptidomimetic) inhibitors with broad spectrum of inhibtion include, for example, N-sulfonyl amino acid hydroxymates that have been orally-available such as CGS27023A and AG3340. Newly developed arylhydroxymate compounds are still being tested for their contingent mutagenic effects. Other non-hydroxymate alternatives of synthetic inhibitors include carboxylic acids and thiols that are able to bind to zinc in the catalytic center of MMP(ref. 116 ). BAY 12-9566 as an example of such an inhibitor is a biphenyl derivate of the anti-inflammatory drug Fenbufen 117 . From carboxylates, inhibitor PD166793 has been successfully used in experimental studies. Administration of this inhibitor to pigs with congestive heart failure helped to diminish dilatation and remodeling of the left ventricle 118 . The same inhibitor prevented the loss of heart mechanical function caused by peroxynitrite 119 . Failing heart in spontaneously hypertensive rats treated by PD166793 had reduced volume of the left ventricle compared to untreated animals where the value of peak +dP/dt was comparable with control animals 120 . In case of rats with spontaneous hypertension, activity of inhibitors reduced left-ventricle dilatation, maintained systolic function, normalized MMP/TIMP expression and reduced the volume of collagenous fraction 121 . Thiol groups, due to their ability to bind zinc at the active site, are incorporated into the molecules of MMPs inhibitors. In spite of the fact that the real afinity of "monodentate" thiol groups is less than "bidentate" carboxylates and hydoxamates, easier solubility and ionization balance their final inhibiting potential 122 .
c) Derivatives of Tetracyclines
Some agents of the group of antibiotics -derivatives of tetracyclines (doxycycline, minocycline and chemically modified tetracyclines (CMT)) are inhibitors of MMPs. These agents inhibit not only activity but also production of MMPs. The inhibiting effect is ensured by both blocking the activity of the enzyme by chelated zinc at the bond site and interference with proteolytic activation of proMMPs; MMPs expression is also reduced 123, 124 . CMT-3 (metastat), which is not toxic and has a long half-life is especially effective 122 .
d) Biphosphonates
Biphosphonates are synthetic analogues of pyrophosphate with high affinity for hydroxypatite crystals of bone tissue; they prevent bone re-adsorption. They are successfully used for the treatment of osteoporosis and other bone diseases. However, in the treatment of cardiovascular diseases they have not been used yet. Mechanisms of MMP activity have not been sufficiently investigated. It has been suggested that their ability to induce production of cytokines results in MMP inhibition [125] [126] [127] .
CONCLUSION AND FUTURE PROSPECTS
This review summarizes some of the recent discoveries that have shed new light on the role of MMPs in remodeling of cardiac tissue. In the past, the role of the extracellular matrix of myocardium was considered to be passive. Development of a whole range of analytic and biochemical approaches has significantly contributed to the clarification of the structure and function of this compartment of heart muscle. Matrix metalloproteinases take part in degradation of extracellular matrix. In mature tissue they have the primary function of repair and protection, more so than in the process of morphogenesis, where their function is completely different. While the discovery that MMPs have a broad range of substrates other than ECM proteins providing new insight into the complexity of their role in tissue remodeling, it also raises numerous questions as to the mechanisms whereby the net effect of their activity is determined. Changed MMP activity is observed above all in impaired tissue. Knowledge of mechanisms of different MMP activation and inhibition may contribute to the treatment of heart diseases. MMPs and their selective synthetic inhibitors will be used not only in the treatment of various oncological diseases but also in diseases of the cardiovascular system.
